Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Nanospectra Biosciences

Nanospectra Biosciences?uq=kzBhZRuG
2002 FOUNDED
PRIVATE STATUS
11-20 EMPLOYEES
Series B LATEST DEAL TYPE
$2.03M LATEST DEAL AMOUNT
8 INVESTORS
Description

Developer of AuroLase Therapy for thermal destruction of solid tumors. The company's AuroLase Ttherapy combines the unique physical and optical properties of AuroShell particles with a near infrared laser source to thermally destroy cancer tissue without significant damage to surrounding healthy tissue.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Therapeutic Devices
Other Industries
Biotechnology
Primary Office
  • 8285 El Rio Street
  • Suite 150
  • Houston, TX 77054
  • United States

+1 (713) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Nanospectra Biosciences’s full profile, request a free trial.

Nanospectra Biosciences Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
16. Later Stage VC (Series B) 09-Feb-2017 $2.03M 00.00 000.00 Completed Clinical Trials - General
15. Later Stage VC (Series AA) 15-Dec-2015 00000 00.00 00.000 Completed Clinical Trials - General
14. Later Stage VC (Series AA) 29-Aug-2014 00000 00.000 00.000 Completed Clinical Trials - General
13. Later Stage VC (Series AA) 17-Jun-2013 00000 00.000 00.000 Completed Clinical Trials - General
12. Later Stage VC (Series AA) 03-Jun-2013 00.000 00.000 00.000 Completed Clinical Trials - General
11. Convertible Debt 16-Nov-2010 00000 00.000 Completed Clinical Trials - General
10. Grant 03-Aug-2010 00.00 00.000 Completed Clinical Trials - General
9. Later Stage VC 05-Jan-2009 00.00 00.000 Completed Clinical Trials - General
8. Corporate 03-Nov-2008 $250K $990K Completed Clinical Trials - General
7. Grant 15-Sep-2008 $350K $740K Completed Clinical Trials - General
To view this company’s complete deal history including valuation and funding, request access »

Nanospectra Biosciences Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series B 0,000,000 00.000000 00 00.00 00.00 00 00.00 000
Series AA 0,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
To view this company’s complete Cap Table, request access »

Nanospectra Biosciences Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Science Applications International Corporation Minority 000 0000 000000 0
Mercury Fund Venture Capital Minority 000 0000 000000 0
Hawaii Angels Angel Group Minority 000 0000 000000 0
Houston Angel Network Angel Group Minority 000 0000 000000 0
MediGen Group Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 8 investors. Get the full list »

Nanospectra Biosciences Executive Team (7)

Name Title Board
Seat
Contact
Info
David Jorden Chief Executive Officer, Executive Director and Board Member
Glenn Goodrich Ph.D Acting Chief Operating Officer & Vice President, Process Development and Chemistry
Jon Schwartz Ph.D Director, Clinical Research
Naomi Halas Ph.D Co-Founder

3 Former Executives

You’re viewing 4 of 7 executives. Get the full list »

Nanospectra Biosciences Board Members (8)

Name Representing Role Since Contact
Info
Bradley Nyberg Self Board Member 000 0000
Brian Pryor Self Board Member 000 0000
David Anderson Self Chairman 000 0000
David Bristol Jr. Self Board Member 000 0000
David Jorden Nanospectra Biosciences Chief Executive Officer, Executive Director and Board Member 000 0000
You’re viewing 5 of 8 board members. Get the full list »